GlassScriptPhysician profile
Sudip Tripathy
NPI 1972570521
$21,318.23
in general payments reported to CMS, 2019-2025
60 companies · $3,196 in 2025
The $3,196 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,466 · 2020: $2,441 · 2021: $3,088 · 2022: $2,918 · 2023: $3,598 · 2024: $3,611 · 2025: $3,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,405.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,593.28 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,631.41 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,453.90 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $1,391.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,370.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,327.52 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,073.27 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $960.09 | 2019-2025 | Spravato, Xarelto |
| Amgen INC. | $885.34 | 2019-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $650.82 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $576.55 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Novartis Pharmaceuticals Corporation | $576.18 | 2019-2023 | |
| Lundbeck LLC | $552.92 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $490.79 | 2022-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $478.45 | 2024-2025 | Voquezna |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudip Tripathy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.